NICE TA974 Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma. NHSE commissioned. (Decision date - June 2024)
NICE TA970 Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments. NHSE commissioned. (Decision date - June 2024)
DNP:
NICE TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) (Decision date - June 2021)
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions